OMC
NBIX icon

Overbrook Management Corp’s Neurocrine Biosciences NBIX Stock Holding History

Overbrook Management Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,157
Closed -$784K – 109
2020
Q3 		$784K Sell
8,157
-240
-3% -$27.8K 0.18% 68
2020
Q2 		$1.02M Buy
+8,397
New +$928K 0.27% 62

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Overbrook Management Corp's NBIX Position: Q4 2020 in Review

Overbrook Management Corp sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 8,157 shares — an estimated $784K sold.

Overbrook Management Corp first reported a position in NBIX in Q2 2020 and held it in 2 quarters. The position peaked at $1.02M in Q2 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Overbrook Management Corp reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Overbrook Management Corp sold 8,157 Neurocrine Biosciences shares in Q4 2020, an estimated $784K.
  • Overbrook Management Corp first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 2 quarters.
  • Overbrook Management Corp's Neurocrine Biosciences position peaked at $1.02M in Q2 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Overbrook Management Corp's 13F filing for Q4 2020, filed 16 Feb 2021.